WHO recommendations on drug treatment for non-severe hypertension in pregnancy

Published by World Health Organization on Apr 3, 2025

Disclaimer

Sponsors

Contact

Abstract

WHO recommendations on drug treatment for non-severe hypertension in pregnancy

ISBN 978-92-4-000879-3 (electronic version) ISBN 978-92-4-000880-9 (print version)

 

© World Health Organization 2020

 

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

 

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

 

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

 

Suggested citation. WHO recommendations on drug treatment for non-severe hypertension in pregnancy. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

 

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
 

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

 

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

 

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

 

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

 

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Language

en-gb

PICOS

PICO 60.1

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Any antihypertensive drug
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.2

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Beta blockers
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.3

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Metyldopa
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.4

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Calcium channel blockers
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.5

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Alpha-blockers
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.6

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Glyceryl trinitrate
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.7

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Sildenafil
Comparator
No antihypertensive drugs/placebo
Outcomes

PICO 60.8

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Beta-blockers
Comparator
Methyldopa
Outcomes

PICO 60.9

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Calcium channel blockers
Comparator
Methyldopa
Outcomes

PICO 60.10

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Ketanserin
Comparator
Methyldopa
Outcomes

PICO 60.11

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Glyceryl trinitrate (GTN)
Comparator
Calcium channel blockers
Outcomes

PICO 60.12

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Furosemide
Comparator
Calcium channel blockers
Outcomes

PICO 60.13

Population
Pregnant women with non-severe (mild to moderate) hypertension during pregnancy
Intervention
Beta-blockers
Comparator
Calcium channel blockers
Outcomes